Microcap Ledger Assembly Biosciences, Inc. $ASMB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 20,360,596 [10-Q 2026-08-13]
What the company doesAI summary of filing
Assembly Biosciences is a clinical-stage biotechnology company developing antiviral therapies for serious viral diseases. The company's pipeline includes investigational treatments for recurrent genital herpes (long-acting helicase-primase inhibitors), hepatitis delta virus (an oral entry inhibitor), hepatitis B virus (a capsid assembly modulator), and transplant-associated herpesviruses (a broad-spectrum polymerase inhibitor). In December 2025, Gilead Sciences exercised its option to exclusively license the company's herpes program, and the company is evaluating partnering opportunities for its hepatitis B program while advancing other candidates through clinical and regulatory filing-enabling studies. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $21.59M | −$12.94M | −$37.59M | $32.29M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $72.30M | −$6.12M | −$41.09M | $58.45M | [10-K 2026-03-19] |
| FY ended Dec 2024 | $28.52M | −$40.18M | −$51.12M | $38.34M | [10-K 2026-03-19] |
- Quarterly cash burn
- −$18.79M
- Cash runway Estimate
- ~5.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 6,356,286 | [10-Q 2024-11-07] |
| 2025-03-14 | 7,503,385 | [10-K 2025-03-20] |
| 2025-05-02 | 7,637,553 | [10-Q 2025-05-08] |
| 2025-08-01 | 7,672,261 | [10-Q 2025-08-06] |
| 2025-11-07 | 15,817,140 | [10-Q 2025-11-10] |
| 2026-03-13 | 15,862,705 | [10-K 2026-03-19] |
| 2026-05-01 | 15,892,608 | [10-Q 2026-05-07] |
| 2026-08-07 | 20,360,596 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-03-19; declared effective 2026-03-27 [S-3 2026-03-19]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-17 | Bjorkquist Jeanette M | sell | 29 | $23.25 | [4 2026-06-18] |
| 2026-03-29 | Gaggar Anuj | grant | 14,000 | — | [4 2026-06-05] |
| 2026-03-29 | White Nicole S | grant | 14,000 | — | [4 2026-06-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Acquisition or disposition completed |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-05 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-27 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-26 | 8-K | Material agreement entered; Other events |
| 2026-05-26 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-22 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-22 | 8-K | Regulation FD disclosure; Other events |
Alerts for $ASMB
Email me when Assembly Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.